Phase 3 trial in fit patients with untreated CLL (166 treated): fixed-duration venetoclax-obinutuzumab vs FCR/BR gave higher undetectable MRD (<10-4) in blood at month 15 (81.3% vs 54.7%; P=.0004). PFS could not yet be evaluated.
RCTn = 166 patients
Sharman et al. Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial